Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb

• https://x.com/synovialjoints/status/1983202097903370743/photo/1

Heydari-Kamjani et al. TriNetX study. 28973 PsA patients. IL-17i and IL-23i lower rates stroke, MI, DVT/PE than TNFi. IL-12/23i higher rate of stroke vs TNFi. @RheumNow #ACR25 Abstr#2363 https://t.co/fNHaxyYPCP

• https://x.com/RichardPAConway/status/1983199075072913874/photo/1

Molina et al. 52 weeks of MANHATTAN study. Guselkumab vs second TNFi after failure 1st TNFi in PsA. MDA 52% vs 33%. Remission/LDA 67% vs 62%. @RheumNow #ACR25 Abstr#2373 https://t.co/qdtOlKLfNU

• https://x.com/RichardPAConway/status/1983197816982823217/photo/1

Hojiej et al. Prevalence and Impact of lifestyle factors in PsA. Lifestyle factors impacted disease activity. Cumulative effect of increasing number of factors @RheumNow #ACR25 Abstr#2309 https://t.co/oDGQyLBRDO

• https://x.com/RichardPAConway/status/1983195551920460244/photo/1

In DISCOVER-2, male PsA patients had greater radiographic progression than females despite similar baseline scores. Early joint response (W8 cDAPSA LDA) was linked to less progression more strongly in men. Highlights the sex differences in PsA outcomes. Abstract#2345 @RheumNow https://t.co/zIo59FYPVg

• https://x.com/synovialjoints/status/1983194545962570145/photo/1

Gender differences in p/axSpA in Turkiye from ASAS-PerSpA: Males - early onset IBP (<45yrs); sacroiliitis on CR, HLA-B27+ (vs. females) Females - peripheral dse, enthesitis, Pso, dactylitis; ⬆️dse activity, FM (vs. males) Individualize & optimize tx. #ACR25 @RheumNow Abs2322 https://t.co/vcisNguJLB

• https://x.com/RHEUMarampa/status/1983190266963202058/photo/1

#ClinicalPearl Pts w #SpA ex #PsA May have 👇 #sicca #dry #eyes #dry mouth Inflamed gallbladder without calculi 👇 Can be associated w #autoimmune disease #POTS can be initial presentation of #SjD IgA vasculitis—May have #cancer #Secrets & #Pearls #ACR25 @RheumNow @ACRheum https://t.co/4SAqVYjnrD

• https://x.com/Janetbirdope/status/1983177607819735191/photo/1

Late-Breaking Trials in axSpA and PsA https://t.co/Fw8wiAPLoN The amazing @Janetbirdope discussing head to head trials in Axial SpA and PsA with primary failure to TNF. To switch to another TNF or IL17? IL17 for my PsA patient for sure. @RheumNow #ACR25

• Late-Breaking Trials in axSpA and PsA

Delay in PsA diagnosis Meta Analysis of 32000+ pts Median diagnostic delay 2.5 years Median delay in referral 1 year Increase odds of Rx damage from 50% Geographic variation We need to do better #ACR25 @RheumNow #ABSTRACT1713 https://t.co/CWwqosa5NT

• https://x.com/AurelieRheumo/status/1982914302769328269/photo/1
• https://x.com/AurelieRheumo/status/1982914302769328269/photo/1